Atlas Trials

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Clinical trial NCT05646836 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05646836
Sponsor
Genentech, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2023-03-21
Primary completion
2026-11-18
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.